Tenax Therapeutics (TENX) SC 13G TENAX THERAPEUTICS / Lind Global Fund II ownership change

Exhibit 99.1

JOINT FILING AGREEMENT

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.0001 per share, of Tenax Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

February 15, 2024

LIND GLOBAL FUND II LP
By:	Lind Global Partners II LLC
	its General Partner
By:	/s/ Jeff Easton
Name:	Jeff Easton
Title:	Managing Member
LIND GLOBAL PARTNERS II LLC
By:	/s/ Jeff Easton
Name:	Jeff Easton
Title:	Managing Member
JEFF EASTON
By:	/s/ Jeff Easton